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CANCER
The spectrum of p53 mutations in colorectal adenomas
differs from that in colorectal carcinomas
X P Hao, I M Frayling, J G Sgouros, M Q Du, T C Willcocks, I C Talbot, I P M Tomlinson
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Gut 2002;50:834–839
Background: p53 mutations are frequently observed in colorectal carcinomas but they have also been
found in colorectal adenomas, although considerably less frequently.
Aims: To explore p53 mutations in benign tumours, we have screened 70 colorectal adenomas for
allelic loss at, and point mutations in, TP53 by analysis of selected microdissected cell populations.
Results: Sixteen (22.8%) adenomas were found to have allelic loss, of which 11 (15.7%) had p53
mutations. In adenomas with mild, moderate, or severe dysplasia, mutation or allelic loss occurred in
4.8%, 16.7%, and 52.6%, respectively (p<0.001). Seven different mutations were found, all missense
changes or inframe deletions: one (Thr150Arg) has not been found before while three (Gln144His,
Gly245Arg, and Glu285Gln) have not been described previously in colorectal tumours. The other
three mutations (Arg175Gly, ∆Pro190, and Gly245Ser) have been found in colorectal carcinomas, the
last commonly. Adenomas harboured a spectrum of p53 mutations which was significantly different
from cancers as regards the position in the gene and a higher frequency of G→C/C→G changes.
Conclusions: Combining our data on adenomas with data already published and in comparison with
the spectrum of mutations in colorectal carcinomas, it is suggested that some p53 mutations have a
weaker effect than others and are therefore more likely to be found in adenomas which have not pro-
gressed to carcinomas.
The p53 protein plays a pivotal role in modulating cellgrowth, division, and apoptosis. Mutant p53 may contrib-ute to increased cell proliferation, loss of ability to
undergo apoptosis, and increasing genetic instability.1 Inacti-
vation of p53 has been found in a wide variety of malignant
tumours, including colorectal cancers, where it is generally
believed to be critically involved in the transition from
adenoma to carcinoma.2 3 Using immunohistochemistry
(IHC), we and others have found nuclear accumulation of p53
protein in colorectal adenomas with moderate and severe
dysplasia,4–6 raising the possibility that not all p53 mutations
which occur in adenomas necessarily lead to rapid or inevita-
ble progression of the tumour to malignancy. However, it is
possible that accumulation of p53 in these cases may involve
unusual mechanisms, without promoting malignancy.
If TP53 mutations were causal or permissive in malignant
progression, it would be reasonable to expect that the
spectrum of mutations in adenomas might be distinct from
that in carcinomas. In this case, the TP53 mutations observed
in adenomas could be explained by the fact that they confer
some advantage to the cells, but are insufficient, at least on
their own, to cause malignancy. If on the other hand there
were no differences in the two spectra, this would be evidence
that it may be some other change, highly correlated with TP53
mutation but independent of its exact nature, which in com-
bination with (or promoted by) the TP53 mutation was the
cause of progression to malignancy. Unfortunately, there are
few data available to address this question. While there have
been numerous reports based on IHC of p53 in adenomas,
there have been few studies of actual TP53mutations or loss of
heterozygosity (LOH), certainly in relation to the number of
studies reporting TP53 mutations in colorectal carcinomas.
Numerous studies have provided data on nearly 800 somatic
TP53 mutations which have occurred in colorectal cancers,
which contrasts with the 22 mutations that have to date been
described in colorectal adenomas7–10; these have usefully been
collated into databases.11 12 Analysis of the mutations found to
occur in colorectal cancers has shown that a high proportion
(approximately 50%) occur at CpG sites, with five codons in
particular (175, 245, 248, 273, and 282) being especially
prevalent sites of mutation.1 3 13
To further explore the nature and significance of TP53
mutations in colorectal tumours, we have studied mutations
in and LOH at TP53 in a large series of adenomas previously
analysed by IHC6 and then, combined with published data,
compared the findings in adenomas with those in carcinomas.
Our results show that the spectrum of TP53 mutations in
adenomas is different from that in carcinomas, thus leading to
the conclusion that, in those cases, it is TP53 mutations per se
which cause or are permissive for malignant progression.
MATERIALS AND METHODS
Tissue samples
Paraffin embedded blocks of 18 p53 IHC positive and 52 IHC
negative colorectal adenomas were retrieved from the archives
of the Academic Department of Pathology at St Mark’s Hospi-
tal. These adenomas were selected according to the following
standard: only patients without a personal or family history of
malignancy or familial adenomatous polyposis were chosen;
all polyps were completely excised by polypectomy or surgical
resection; and the adenomas selected were the largest in size
and severest in grade of dysplasia if multiple. All patients pre-
sented symptomatically. Histology was reviewed by two
histopathologists (ICT, XPH). Serial 6 µm sections were cut
and lightly stained with haematoxylin and eosin for microdis-
section. IHC methods and results have been previously
reported.6
Microdissection and DNA preparation
In p53 IHC positive tumours, p53 positive cells were
specifically microdissected from lightly stained haematoxylin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Abbreviations: IHC, immunohistochemistry; LOH, loss of heterozygosity;
PCR, polymerase chain reaction; SSCP, single strand conformational
polymorphism.
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and eosin slides by comparison with immunostained slides.
For the p53 IHC negative tumours, areas of dysplastic cells
were microdissected from lightly stained haematoxylin and
eosin slides. In both IHC positive and negative tumours, cells
were also microdissected from histologically normal mucosa.
The microdissected cell populations were digested in 100 µl of
1× polymerase chain reaction (PCR) buffer without magne-
sium (Promega Corporation, Madison, Wisconsin, USA)
containing 200 mg/l proteinase K, for 24–48 hours at 55°C.
Proteinase K was thereafter inactivated by heating to 96°C for
10 minutes, the cell debris pelleted by centrifugation (12 000
g for five minutes), and the supernatant used for PCR.
SSCP analysis
As the majority of TP53 mutations occur at conserved regions
in exons 5, 6, 7, 8, and 9,14 15 these exons were amplified by PCR
(exons 5, 6, and 7 separately, exons 8 and 9 in one amplicon),
and mutations screened for by single strand conformational
polymorphism (SSCP) analysis.7 For reliable amplification
using DNA extracted from formalin fixed and wax embedded
tissues, a touch down thermal cycling programme with hot
start was employed, and PCR was carried out for 46 cycles of
amplification. Each cycle consisted of 94°C for 60 seconds, an
annealing step at a variable temperature for 60 seconds, and
an extension step of 72°C for 45 seconds. For the first cycle the
annealing temperature was 60°C, reducing to 59°C in cycle 2,
58°C in cycle 3, 57°C in cycles 4–7, 56°C in cycles 8–11, and
55°C in cycles 12–46. Cycling was preceded by an initial dena-
turation step of four minutes at 95°C, and followed by a final
elongation step of five minutes at 72°C. PCR products were
analysed by SSCP using a temperature controlled semidry
electrophoresis machine (Genephor, Pharmacia, USA) utilis-
ing dedicated precast 12.5% polyacrylamide gels (GeneGel
Excel 12.5) as directed by the manufacturer. PCR products
were combined in pairs, either exon 5 plus exon 7, or exon 6
plus exons 8+9, and then diluted and denatured according to
the instructions; the equivalent of 0.5 µl of each individual
PCR product was loaded per lane. Electrophoresis was
performed for 60minutes at a constant 900 V; all samples were
analysed twice, once at 5°C and a second time at 20°C. The gels
were silver stained according to the manufacturer’s recom-
mendations, and viewed by two observers (XPH and IMF) to
maximise the efficiency of mutation detection.
DNA sequencing
Exons in which mutations were putatively identified by SSCP
were sequenced using an ABI PRISM 377 fluorescent DNA
analyser (Perkin-Elmer Applied Biosystems, Foster City,
California, USA). Dye deoxy terminator ready reaction mix
(Perkin-Elmer Applied Biosystems) was used according to the
manufacturer’s instructions and using an annealing tempera-
ture of 51°C for five seconds. Results were analysed by three
observers (XPH, IMF, and IPMT) using Sequence Navigator
software (Perkin-Elmer Applied Biosystems).
LOH analysis
Allelic loss (LOH) at the TP53 locus was tested for by analysis
of three flanking microsatellites: D17S1176, D17S1881, and
TP5316 17 in the paired tumour and normal tissues. Oligonucle-
otide primers were labelled with fluorescent dyes to allow
analysis using an ABI PRISM 377 fluorescent DNA analyser
and GeneScan software (version 2.1.2; Perkin-Elmer Applied
Biosystems), as previously described.18
Statistical analysis
The χ2 test or Fisher’s exact test (two sided) was used to deter-
mine the statistical significance of associations between the
molecular and clinical data. The χ2 test, on loge transformed
data with Pearson’s correction, was used to determine the log
Table 1 Details of adenomas with positive p53 immunohistochemistry (IHC), mutations in or loss of heterozygosity
(LOH) at TP53
No Sex
Size
(cm) Type Site Dysplasia IHC LOH
Mutation
Location Codon
Nucleotide
change Consequence
ICsm0997 F 3.0 T R Moderate + − −
ICsm0656 F 0.6 T R Moderate + − −
ICsm0677 F 1.3 T R Moderate + − −
ICsm1231 M 1.8 T S Moderate ++ − −
ICsm1131 F 2.2 T S Severe +++ − −
ICsm0522 M 1.3 T S Moderate − + −
ICsm0741 F 0.7 TV S Moderate − + −
ICsm0740 F 1.0 T S Moderate + + −
ICsm1186 M 1.5 TV R Moderate +++ + −
ICsm0951 M 3.2 TV S Severe ++ + −
ICsm1300 F 2.0 TV R Severe +++ + Exon 5 144 432G→C Gln144His
ICsm1169 M 1.2 TV S Severe +++ + Exon 5 150 449C→G Thr150Arg
ICsm0712 F 1.7 T R Mild + + Exon 5 175 523C→G Arg175Gly
ICsm0976 M 0.7 TV S Severe ++ + Exon 6 192 572delCTC ∆Pro190
ICsm0824 M 1.5 T R Severe + + Exon 7 245 733G→A Gly245Ser
ICsm0937 F 3.0 TV S Severe ++ + Exon 7 245 733G→C Gly245Arg
ICsm0798 M 2.2 TV T Moderate + + Exon 7 245 733G→A Gly245Ser
ICsm1195 M 3.5 TV S Severe + + Exon 7 245 733G→A Gly245Ser
ICsm1276 M 0.9 TV S Severe + + Exon 7 245 733G→A Gly245Ser
Intron 8 IVS8+26 Splicing?
ICsm0589 M 1.2 T R Severe − + Exon 8 285 853G→C Glu285Gln
ICsm0599 F 1.5 T S Severe +++ + Exon 8 285 853G→C Glu285Gln
Table 2 Correlation between mutations in and loss of
heterozygosity (LOH) at TP53
Mutations
+ −
LOH
+ 11 5
− 0 54
p<0.001 by Fisher’s exact test.
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likelihood ratio for the comparison of mutational position in
the different tumour types.
Previously described TP53 mutations
For comparison with previously described somatic TP53
mutations, advantage was taken of the IARC database of p53
gene mutations in human tumours and cell lines (http://
www.iarc.fr/p53/homepage.htm). Version (R1) was imported
into Microsoft Access for Windows 95 (v7.00). Adenoma data
were also gleaned from the p53 Data Base (http://
perso.curie.fr/Thierry.Soussi/), care being taken to eliminate
entries duplicated on both databases. For determination of
TP53mutation frequencies in colorectal carcinomas, data were
excluded from tumours other than adenomas or carcinomas
(for example, carcinoids), cell lines, familial cases, silent
mutations, and mutations in exons 1, 2, 3, 4, 10, or 11.
RESULTS
The results of the p53 mutation screen and LOH analysis are
summarised in table 1.
Eleven adenomas had mutations which in all cases were
found together with LOH; thus mutation and LOH were
Figure 1 A section from adenoma ICsm0824 with two areas of
tubular (left side, severe dysplasia; right side, moderate dysplasia;
arrows) and one area of villous (arrowhead) architecture with severe
dysplasia. The attached sequencing electropherograms, derived from
material microdissected from each area, show that the same TP53
exon 7 mutation (GGC→AGC; Gly245Ser) is present in all three
areas.
A
40
Normal
tissue
G G G C G G C G G G C A
30 40
G C
G G G C G C G G G C A G C
Table 3 Mutations in or loss of heterozygosity (LOH)
at TP53 by histological grade and size
Mutation or LOH
p Value+ −
Dysplasia
Mild 1 20
Moderate 5 25 <0.0008
Severe 10 9
Size
<1 cm 4 21 >0.35
>1 cm 12 33
Fisher’s exact test, mild plus moderate versus severe, <1 cm versus >1
cm.
Table 4 Correlation between p53 immunohistochemi-
stry (IHC) and mutations in or loss of heterozygosity
(LOH) at TP53
Mutation or LOH
+ −
IHC
+ 13 5
− 3 49
p<0.001, Fisher’s exact test.
Figure 2 The frequency of somatic TP53 mutations found in
colorectal adenomas (n=33) and carcinomas (n=782) between
codons 125 and 306 (exons 5–9), given as a percentage and
plotted by codon (data from this study, and Hainaut and colleagues11
and Beroud and Soussi12). Whereas the commonest site of mutation
in carcinomas (codon 248) is underrepresented in adenomas, a
mutation at codon 245, the fourth commonest site in carcinomas, is
the commonest site in adenomas. Mutations at codons 144 and 150
have only been found in adenomas.
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Table 5 Comparison of the TP53 mutational spectra
of colorectal adenomas and carcinomas
Codons Carcinomas Adenomas
126–174, 176–244, 246–247,
249–272, 274–281, and 283–306
439 13
175 83 6
245 47 7
248 108 1
273 61 4
282 44 2
All 782 33
χ2=14.98 on loge transformed data; log likelihood ratio=0.01.
Data combined from this study and public databases.11 12
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strongly correlated (p<0.001, Fisher’s exact test) (table 2). Ten
of the mutations were missense changes and one was a 3 bp
deletion having the effect of removing one of the two proline
residues at codons 190 and 191 (∆Pro190; table 1). Adenoma
ICsm1169 was found to have a missense point mutation not
previously described in any form of neoplasm (449G→C;
Thr150Arg). Another adenoma (ICsm1276) with a missense
mutation in exon 7 (Gly245Ser) and LOH had a second
sequence variant of uncertain significance, an insertion of AT
in place of a G in intron 8 (IVS8+26delGinsAT). Interestingly,
in one adenoma (ICsm0824) it was possible to show that both
the pattern of LOH and the same mutation (Gly245Ser) were
present in three histologically distinct areas, one tubular area
with moderate dysplasia, and one tubular and one villous area
with severe dysplasia (fig 1).
Given the strong correlation between mutations and LOH
(table 2), tumours with either of these events were combined in
a single group for further statistical analysis. Severely dysplastic
adenomas displayed a significantly increased frequency of
mutation or LOH compared with those with mild andmoderate
dysplasia (p<0.001, χ2 test) (table 3) but there was no correla-
tion with size (p>0.25; χ2 test) or histological type (tubular v
tubulovillous plus villous) (data not shown). Positive IHC was
correlated with mutation or LOH (table 4) but the relationship
was not absolute: three IHC negative adenomas and three of
eight IHC positive but mutation negative adenomas were found
to have LOH.
Data available from other studies on TP53 mutations in
adenomas (n=22) were combined with our data (n=11) and
the sites of the mutations were plotted on a multiple
alignment of p53 sequences from human plus seven other
mammalian species (details not shown). All mutations
observed in adenomas occurred at residues either absolutely
or highly conserved. An initial comparison (fig 2) was then
made of the combined adenoma data with those available11 12
on p53mutations in colorectal carcinomas (n=782). From this
Table 6 TP53 mutations in colorectal carcinomas found at the same codons as in
adenomas
Normal Codon Mutant
Adenomas* Carcinomas†
No % No %
Phe 134 Leu 1 0.1‡
Ser 1 3.0 1 0.1
Gln 144 His§ 1 3.0
Thr 150 Arg 1 3.0
Gly 154 Asp 1 3.0 1 0.1
Arg 175 Cys 2 0.3
Gly 1 3.0 1 0.1
His 6 18.2 74 9.5
Leu 4 0.5
Pro 1 0.1
Ser 1 0.1
Arg 213 Gln 1 0.1
Leu 1 0.1
Stop 1 3.0 15 1.9
Met 237 Frameshift 1 0.1
Ile 6 0.8
Leu 1 3.0 1 0.1
Lys 1 0.1
Ser 241 Cys 1 3.0 2 0.3
Frameshift 2 0.3
Phe 8 1.0
Gly 244 Asp 2 0.3
Cys 3 0.4
Ser 2 0.3
Val 1 3.0 1 0.1
Gly 245 Arg 1 3.0
Asp 1 3.0 13 1.7
Cys 4 0.5
His 1 0.1
Ser 5 15.2 25 3.2
Val 4 0.5
Arg 248 Gln 51 6.5
Leu 2 0.3
Trp 1 3.0 54 6.9
Phe 270 Cys 1 0.1
Ile 1 3.0 3 0.4
Arg 273 Cys 1 3.0 32 4.1
His 3 9.1 27 3.5
Arg 282 Gln 3 0.4
Leu 1 0.1
Trp 2 6.1 40 5.1
Glu 285 Asp 1 0.1
Gln 2 6.1
Lys 2 0.3
Stop 1 0.1
Arg 290 Frameshift 1 3.0 1 0.1
His 1 0.1
*This study plus data from public databases.11 12
†As in the public databases.11 12
‡Percentage of the 782 colorectal carcinomas described in the public databases.11 12
§Gln144Stop mutation has been described in a herititary non-polyposis colorectal cancer.24
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it appeared that although the two mutational spectra were
broadly similar, there were differences in detail: firstly, the
commonest site of mutation in carcinomas (13.8%) at codon
248 was relatively underrepresented in adenomas (3.0%),
where instead the commonest site was codon 245 (21.2% v
6.0% in carcinomas); and secondly, in adenomas there were
four mutations at the 5′ end of the gene (Phel34Ser,
G1n144His, Thrl50Arg, and Glyl54Asp) which had been
described rarely, if at all, in colorectal carcinomas. Statistical
analysis of the frequency of mutations observed between
codons 126 and 306 (exons 5–9) at the five commonest sites in
carcinomas, plus all other codons between 126 and 306 com-
bined, gave a log likelihood ratio of 0.01, supporting the
hypothesis that the mutational spectra differed in distribution
(table 5). A third point of contrast became evident when the
nature of the mutations occurring at the same codon in both
tumour types was considered (table 6). From this table it can
be seen that there were frequent differences between the two
tumour types; for example, while codon 245 was the fourth
most common site in carcinomas, it was themost common site
in adenomas because of both overrepresentation of the
Gly245Ser mutant and a mutation never seen in carcinomas
(Gly245Arg) which was observed in one adenoma. Similarly,
codon 285 was an uncommon site for mutations in
carcinomas (0.5%) but in adenomas it was a frequent site
(6.1%) and, moreover, all because of a mutation (Glu285Gln)
only seen in adenomas. Finally, consideration of the frequency
of nucleotide changes in adenomas and carcinomas (table 7)
showed G→C/C→G changes to be significantly more common
in adenomas than in cancers (Fisher’s exact test, p<0.00026).
The reasons for this excess of G→C/C→G changes are unclear,
with no obvious explanation in terms of extrinsic mutagens or
intrinsic hypermutability.
DISCUSSION
We have found in sporadic colorectal adenomas that
mutations in, and LOH at, TP53 are significantly correlated
both with each other and with severe dysplasia. To analyse the
mutation and LOH profile in colorectal adenomas, we took
care that DNA samples were specifically extracted from
microdissected p53 IHC positive cells or from areas of defined
morphology in negatively staining cases, thereby minimising
possible contamination by non-neoplastic tissues, or mixing of
different grades of dysplasia. We found that 52.6% (10/19)
(table 3) of severely dysplastic adenomas exhibited mutations
and LOH,which is in line with a previously reported frequency
of LOH of 45% in highly dysplastic adenomas.19 It also closely
matches a frequency of 50–55% which has been reported in
carcinomas.3 Together these results show that TP53 mutations
frequently occur at the severely dysplastic stage in sporadic
adenomas, before the transition to carcinoma.
We found one adenoma with moderate and severe dysplasia
in two discrete tubular areas and one area of villous histology
with severe dysplasia, all showing the same point mutation
and pattern of LOH. This clonal homogeneity implies that the
TP53 mutation was a relatively early event which preceded the
divergence in architecture and grade of dysplasia in this
adenoma, and suggests that this histological feature is
unrelated to TP53 status, at least in this tumour.
Two adenomas with mutations and one with LOH were
negatively immunostained for p53, despite our use of a sensi-
tive method for antigen retrieval and the use of the antibody
Do-7, which can recognise both wild and mutant p53. Similar
findings have been previously reported.7 9 One explanation
could be that the half life of mutant p53 may not always be
increased enough to permit detectable levels of protein.20 21
Alternatively, p53 protein expression may be transcriptionally
modulated by other proteins such as mdm-2. Our mutation/
LOH positive but p53 IHC negative tumours may harbour
mutations in mdm-2 or related genes. The extent to which
mdm-2 influences p53 expression in colorectal neoplasms
warrants further investigation. Four adenomas showing posi-
tive immunostaining were found neither to harbour muta-
tions nor to show LOH. The explanation for this probably lies
in the fact that no single mutation detection technique is
100% efficient,we sought mutations only in exons 5–9, and we
did not assess transcriptional silencing of p53. These factors
may also explain why we detected LOH at a higher frequency
than p53 point mutations (although we cannot exclude the
possibility that LOH occasionally targeted a different locus on
17p).
Only three of the seven different point mutations which we
found in adenomas (table 5) have been described among the
many hundred TP53 mutations seen in colorectal cancers, and
only Gly245Ser commonly so.11 12 The remaining four muta-
tions have not been found in colorectal carcinomas, and one
(Thr150Arg) has never been seen before in any form of
neoplasia. Gln144His, Gly245Arg, and Glu285Gln, although
found in other types of malignancy, have not been described in
colorectal carcinomas or adenomas. In addition, Gly245Ser
and Glu285Gln were each found independently in more than
one adenoma, suggesting that they are not rare events. The 3
bp deletion having the effect of an inframe deletion of one
amino acid (∆Pro190) has been previously described in three
colorectal cancers, an acute lymphatic leukaemia, and an
astrocytic glioma. Arg175Gly has been found in one colorectal
carcinoma but by far the commonest observed mutation in
Table 7 Mutation spectrum in terms of base change in adenomas and carcinomas
This study
(adenomas)
Previous studies
(adenomas) All adenomas Carcinomas Total
INS/DEL 1 1 2 92 94
A→C 1 1 10 11
A→G 0 59 59
A→T 0 18 18
C→A 0 21 21
C→T 6 6 291 297
G→A 4 12 16 431 447
G→T 1 1 85 86
T→A 1 1 25 26
T→C 1 1 35 36
T→G 0 17 17
C→G 2 2 4 17 21
G→C 4 4 34 38
Total 11 25 36 1135 1171
Data combined from this study and public databases.11 12
Coding strand change is shown.
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colorectal cancers at this codon is Arg175His (table 5). In no
case did we detect “three hits” at p53 in any colorectal
adenoma, although this phenomenon has been reported in
some carcinomas.22
Our analysis of the mutational spectra in colorectal adeno-
mas and carcinomas shows that they differ in both site
(codon; table 5) and probably also type (amino acid substitu-
tion, table 6 and base change, table 7).While it is possible that
some bias has been introduced by differences between studies
in the mutation detection methods used, SSCP analysis has
been frequently used to find TP53 mutations. Similarly, we
confined our studies to the most frequently studied exons5–9
and only took published data from the same region; thus any
bias caused by differences inmethods between studies is likely
to be small.
Taken together, the data suggest that the TP53 mutation
spectra in colorectal adenomas and carcinomas are broadly
similar, supporting the notion that most TP53 mutations are
directly or indirectly involved in the transition from an
adenoma to a carcinoma. That the TP53 mutations seen in
adenomas are at amino acid residues either absolutely or
highly conserved between mammalian species, and that they
are accompanied by allelic loss, provides evidence that they are
of functional significance rather than some chance phenom-
enon. However, we have found notable and specific differences
in mutation spectra between adenomas and carcinomas,
implying that some TP53 mutations, although conferring a
selectable growth advantage, may be either incapable of
effecting malignant transformation (at least on their own), or
may even be incompatible with it. This hypothesis is supported
by recent data from Greenblatt and colleagues22 which suggest
that codon 144mutations affect buried amino acid residues on
the non-DNA binding side of the p53 molecule and may have
relatively weak effects. Codon 150 mutations moreover have
little or no effect in in vitro assays of p53 function,23 suggest-
ing that they too are only weakly selected. An alternative, but
perhaps less likely, explanation for our data is that the differ-
ent mutation spectra might reflect the effectiveness of differ-
ent extrinsic carcinogens or intrinsic genomic instability in
promoting carcinogenesis. Although we recognise that con-
firmatory data are needed, we suggest, in summary, that some
p53 mutations are better than others at promoting (or permit-
ting) progression from colorectal adenoma to carcinoma.
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